Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months $300+ million market cap now. If RadioPharm Theranostics repeats what Monopar does we will all be happy.
From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology company has made a remarkable comeback.
The company we are referring to is Monopar Therapeutics Inc. (MNPR), developing ALXN1840 for Wilson Disease and MNPR-101 as a novel radiopharmaceutical targeting uPAR (urokinase-type plasminogen activator receptor), which is expressed in numerous tumor types including pancreatic, breast, colorectal, and bladder.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
-0.003(8.82%) |
Mkt cap ! $73.31M | |||
| Open | High | Low | Value | Volume |
| 3.4¢ | 3.4¢ | 3.1¢ | $58.95K | 1.821M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 783888 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 870662 | 1 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| RAD (ASX) Chart |